Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Inclusion Criteria:

Eligible patients will be women with stages II-IV epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who have completed standard therapy for primary or recurrent disease (i.e., patients who would normally be observed); eligible patients may have asymptomatic residual measurable disease on physical examination and/or computed tomography (CT) scan, and/or may have an elevated cancer antigen 125 (CA-125); or may be in complete clinical remission after treatment for primary or recurrent disease; these patients would normally enter a period of observation after standard management
Any human leukocyte antigen (HLA) type; (historic HLA typing is permitted)
Tumor expression of NY-ESO-1 or cancer/testis antigen 2 (LAGE-1) by immunohistochemistry (IHC) and/or real-time polymerase chain reaction (RT-PCR)
No allergy to eggs
Life expectancy > 6 months
Hematology and biochemistry laboratory results within the limits normally expected for the patient population, without evidence of major organ failure
Absolute neutrophil count (ANC) >= 1,000/uL
Platelet >= 75,000/uL
Hemoglobin (Hgb) >= 8 g/dL
Total bilirubin =< 1.5 x upper limit of normal (ULN)
Serum glutamic oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST) or serum glutamic pyruvic transaminase (SGPT)/alanine aminotransferase (ALT) =< 3 x ULN
Serum creatinine =< 2 x ULN
Prothrombin time (PT)/international normalized ratio (INR) =< 1.5
Electrocardiogram, showing no evidence of congestive heart failure, myocardial infarction, and cardiomyopathy
Have been informed of other treatment options
Patient or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure
Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of =< 2
Demonstrate the ability to swallow and retain oral medication
Patients of child-bearing potential must agree to use acceptable contraceptive methods (e.g., double barrier) during treatment
Patients may have received previous NY-ESO-1 vaccine therapy

Exclusion Criteria:

Metastatic disease to the central nervous system for which other therapeutic options, including radiotherapy, may be available
Other serious illnesses (e.g. serious infections requiring antibiotics, bleeding disorders)
History of severe autoimmune disorders requiring use of steroids or other immunosuppressives
Concomitant systemic treatment with corticosteroids, anti-histamine or nonsteroidal anti-inflammatory drugs and other platelet inhibitory agents, strong inhibitors/inducers of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP450-3A4)
Chemotherapy, radiation therapy, or immunotherapy within 4 weeks prior to first dosing of study drug (6 weeks for nitrosoureas); concomitant hormonal therapies for breast cancers are allowed
Known allergy or history of life threatening reaction to GM-CSF
Clinically significant heart disease (N-YHA Class III or IV)
Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first dosing of study drug
Known hepatitis B, hepatitis C, or HIV
Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study
Lack of availability of a patient for immunological and clinical follow-up assessment
Known pulmonary hypertension
Known hypersensitivity to sirolimus
Evidence of current drug or alcohol abuse or psychiatric impairment, which in the investigator's opinion will prevent completion of the protocol therapy or follow-up
Pregnant or nursing female patients
Unwilling or unable to follow protocol requirements
Any condition which in the investigator's opinion deems the patient an unsuitable candidate to receive study drug; (i.e., any significant medical illness or abnormal laboratory finding that would, in the investigator's judgment, increase the subject's risk by participating in this study)